Nexus Energy Services, Inc. Q3 FY2024 earnings call

• RUCONEST remains a key pillar, delivering significant cash flows. It has more than 800 prescribers, with 57 new prescribers in 2024, and double-digit revenue growth. - Joenja's US launch had a strong start, with ongoing efforts to find patients globally, including nearly 900 patients in various access programs. - Efforts to find APDS patients through education, sponsored no-cost testing, and resolving variants of uncertain significance. - Started a Phase 2 trial for leniolisib in a larger primary immune deficiency indication with immune dysregulation.

RUCONEST: In 3Q 2024, RUCONEST generated over $64 million in revenue, with nearly $173 million for the first nine months of 2023. It continues to grow in the hereditary angioedema market with more prescribers and patients. Joenja: For the first nine months of 2024, Joenja's revenue was $32 million. It had a strong US launch, with ~50% of known APDS patients found in 18 months, 25% pediatric, 93 adult patients on paid therapy, and 5 pending insurance authorizations in Q3.

• Expect total revenues to land in the midpoint of $82 million to $95 million. - Joenja to continue driving revenue growth with expected patient growth and over 85% adherence. - OpEx for Q4 expected to be at similar levels to prior quarters this year.

• Challenges in patient identification and insurance authorization for Joenja. - Uncertainties in the pace of Joenja's global rollout and market adoption. - Dependence on successful regulatory approvals and clinical trial outcomes for new indications.

Q: On RUCONEST, do you see refills happening from previous quarters and how do you see the ODP market developing?

A: Yes, refills reflect patient's disease course. The ODP market is stable with over 50% of patients still having regular acute attacks, and RUCONEST serves a severe patient segment not well-treated by other therapies.

Q: For Joenja in the UK, how are discussions with NICE progressing and how many US patients do you expect to convert to Joenja?

A: Discussions with NICE are productive but confidential. For US patients, all eligible patients wanting therapy are expected to eventually be on therapy, with different insurance processes but no refusals so far.

Q: Plan for remaining convertible bonds and headwinds for Joenja?

A: Current convertible bond is kept on the market with no immediate redemption plan. Headwinds include slowing growth after initial patient bolus, but patient funnel is building for future growth.

Q: Update on Joenja approvals, rollout ex US and timelines?

A: Continuing progress on EU CMC issue, expect to file in Japan mid-2025, pediatrics data soon for filing in second half of 2025, and ongoing reviews in Australia, Canada, etc.